Biogennix named Michael Roux as the orthobiologic company's new general manager. By Shayna Korol - 1/16/19

The global platelet rich plasma market is expected to hit $400 million by 2023, growing at a 13.3 percent compound annual growth rate, according to a Qurate Business Intelligence report. By Jackie Drees - 1/16/19

The global orthopedic biomaterials market is expected to grow at a 7 percent compound annual growth rate between 2018 and 2022, according to a Technavio report. By Shayna Korol - 1/15/19

Bioventus launched its Osteomatrix+ bone graft for various spine and orthopedic applications. By Shayna Korol - 1/15/19

Orthopedic fixation company Ossio received FDA 510(k) clearance for its Ossiofiber Bone Pin Family. By Shayna Korol - 1/14/19

Marco Rodriguez, MD, founder of Baton Rouge, La.-based International Spine Institute, is using regenerative stem cell therapies as an alternative to spinal surgery. By Mackenzie Garrity - 1/14/19

Generex Biotechnology Corp. signed a letter to purchase Medisource Partners, an FDA-registered distributor. By Mackenzie Garrity - 1/11/19

SpinalCyte received a new Australian patent related to its fibroblast technology. By Shayna Korol - 1/8/19

DiscGenics' injectable disc cell therapy, IDCT, passed the initial safety review of its first-in-human trial for moderate degenerative disc disease treatment. By Shayna Korol - 1/8/19

JRF Ortho provides allograft joint repair solutions. By Shayna Korol - 1/7/19

The FDA granted StemCyte permission to proceed with its phase 2 investigational new drug application for the Allogenic Human Leukocyte Antigen-Matched Umbilical Cord Blood Mononuclear Stem Cells (MC001). By Mackenzie Garrity - 1/4/19

Carmell Therapeutics, a developer of plasma-based bioactive materials to accelerate bone and soft tissue healing, welcomed Wendy DiCicco to its board of directors. By Mackenzie Garrity - 1/3/19

The Department of Defense granted a team of researchers at the University of Arizona in Tucson $2 million to study bone regrowth technology, according to The Brunswick News. By Mackenzie Garrity - 1/2/19

Orthobiologics may become a mainstream treatment for knee osteoarthritis, according to orthopedic sports medicine surgeon Bert Mandelbaum, MD, in a Medscape column. By Shayna Korol - 12/21/18

Michael B. Gerhardt, MD, is a sports medicine specialist and orthopedic surgeon at Cedars-Sinai Kerlan-Jobe Institute in Los Angeles and team physician for the LA Galaxy and U.S. Soccer Men's National Team. By Laura Dyrda - 12/26/18

Here are 10 must-read Q&As from 2018 on biologics. By Mackenzie Garrity - 12/26/18

Robert LaPrade, MD, is an orthopedic surgeon based in Colorado. By Laura Dyrda - 12/22/18

The FDA warned Genetech and its president Edwin Pinos for manufacturing stem cell products without FDA approval and deviating from current good manufacturing practice requirements, which may have led to microbial contamination. By Shayna Korol - 12/22/18

The FDA recently vowed to crackdown on unsubstantiated and poor quality stem cell therapies in 2019. Biologic-based products and other emerging medical technologies are at the center of a debate over the best regulatory pathways to ensure patient safety. By Shayna Korol - 12/21/18

A U.S. nonprofit organization found Biogen Inc's Spinraza treatment for spinal muscular atrophy and Novartis AG's experimental gene therapy are both expensive but have the potential to be more cost effective with additional research, according to Reuters. By Mackenzie Garrity - 12/21/18